Drugs on the horizon for diabesity.
The coexistence of type 2 diabetes and obesity presents a complex therapeutic challenge. Future combination tablets may include agents to address diabetes and any accompanying cardiovascular risk factors. Injectable agents that improve glycemic control and facilitate weight loss have recently become available: the soluble amylin analogue pramlintide provides an adjunct to insulin therapy in type 1 and type 2 diabetes, and the incretin mimetic exenatide can enhance prandial insulin release in type 2 diabetes. Orally active inhibitors of the incretin-degrading enzyme dipeptidyl peptidase-IV, agonists of peroxisome proliferator-activated receptor (PPAR)-a and PPAR-g ("dual PPARs"), and the CB1 cannabinoid receptor inhibitor rimonabant are advanced in clinical development. Many novel antidiabetic and antiobesity compounds are emerging in preclinical development.
Bailey
Clifford J
CJ
Diabetes Group, Life and Health Sciences, Aston University, Aston Triangle, Birmingham B4 7ET, UK. c.j.bailey@aston.ac.uk
D058892:Adenosine Deaminase Inhibitors; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D018819:Dipeptidyl Peptidase 4; D015195:Drug Design; D004435:Eating / Q000502:physiology; D006023:Glycoproteins / Q000037:antagonists & inhibitors; D006801:Humans; D007004:Hypoglycemic Agents / Q000138:chemical synthesis / Q000627:therapeutic use*; D007328:Insulin / Q000378:metabolism; D000078790:Insulin Secretion; D047493:PPAR alpha / Q000819:agonists; D047495:PPAR gamma / Q000819:agonists / Q000037:antagonists & inhibitors; D011480:Protease Inhibitors / Q000627:therapeutic use
D058892:Adenosine Deaminase Inhibitors; D006023:Glycoproteins; D007004:Hypoglycemic Agents; D007328:Insulin; D047493:PPAR alpha; D047495:PPAR gamma; D011480:Protease Inhibitors; C042807:DPP4 protein, human; D018819:Dipeptidyl Peptidase 4